TSS
RLMD icon

Two Sigma Securities’s Relmada Therapeutics RLMD Stock Holding History

Two Sigma Securities’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-14,012
Closed -$3.78K – 1989
2025
Q1 		$3.78K Buy
+14,012
New +$4.64K ﹤0.01% 1319

Other funds holding RLMD

DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Corient Private Wealth
Corient Private Wealth Miami, Florida $69.9B AUM 22.19% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return

Two Sigma Securities's RLMD Position: Q2 2025 in Review

Two Sigma Securities sold out of Relmada Therapeutics (RLMD) in Q2 2025, closing a stake of 14,012 shares — an estimated $3.78K sold.

Two Sigma Securities first reported a position in RLMD in Q1 2025 and held it in 1 quarter. The position peaked at $3.78K in Q1 2025. 50 funds tracked by Wall St. Rank hold RLMD as of Q2 2025.

  • Two Sigma Securities reported no remaining Relmada Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Two Sigma Securities sold 14,012 Relmada Therapeutics shares in Q2 2025, an estimated $3.78K.
  • Two Sigma Securities first reported a position in Relmada Therapeutics in Q1 2025 and held it in 1 quarter.
  • Two Sigma Securities's Relmada Therapeutics position peaked at $3.78K in Q1 2025.
  • 50 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2025.

Based on Two Sigma Securities's 13F filing for Q2 2025, filed 14 Aug 2025.